MARAVIROC SAFETY & PHARMACOKINETICS IN HIV-EXPOSED NEONATES
Lack of adequate safety and pharmacokinetic (PK) data limits antiretroviral (ARV) prophylaxis and treatment options in HIV-exposed neonates. Maraviroc (MVC), a CCR5 receptor antagonist approved for use in adults, has potential for use in prophylaxis and treatment of HIV-exposed or infected neonates. IMPAACT 2007 is an ongoing Phase I, multi-center, open-label study of MVC safety…